NCT06873087View on ClinicalTrials.gov

Changes in PACAP, CGRP, and VIP Levels in Rosacea Patients on Systemic Isotretinoin and Their Association with Erythema

PHASE4CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 1, 2023

Primary Completion Date

June 30, 2024

Study Completion Date

June 30, 2024

Conditions

Rosacea

Interventions

DRUG

İsotretinoin

Isotretinoin treatment at a dose of 0.3 mg/kg/day for 3 months

Trial Locations (1)

Unknown

Istanbul Training and Research Hospital, Istanbul

All Listed Sponsors

lead

SB Istanbul Education and Research Hospital

OTHER

NCT06873087 - Changes in PACAP, CGRP, and VIP Levels in Rosacea Patients on Systemic Isotretinoin and Their Association with Erythema | Biotech Hunter | Biotech Hunter